RecruitingPhase 2NCT07046910

Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection

Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant


Sponsor

University of Virginia

Enrollment

60 participants

Start Date

Apr 1, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

Lung transplantation (LT) is the only definitive therapy for many patients with end-stage lung diseases. The supply of donors' lungs is the biggest bottleneck to performing a lung transplant, and many patients die while waiting. Acute Cellular Rejection (ACR) is a significant risk factor for developing chronic allograft failure, a primary reason for death in this patient population. These observations highlight the importance of early diagnosis and management of ACR to prevent chronic graft failure. The preliminary results support the idea that Hyperpolarized Gas Magnetic Resonance Imaging has excellent potential to address this clinical gap. This study hypothesizes that optimized hyperpolarized gas magnetic resonance imaging (HGMRI) signatures can detect early pathophysiologic derangements in lung allografts consistent with ACR. This study also hypothesizes that the optimized HGMRI signatures will correlate with single-cell transcriptomic signatures that reflect dysregulated immune responses associated with ACR.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Hyperpolarized Xenon129 and Sub study (Active): Two Lung MRI study with two navigational Bronchoscopy for people with lung transplant rejection. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTSub study (Active): Two Lung MRI study with two navigational Bronchoscopy

Hyperpolarized Xenon-129 MRI twice with navigational bronchoscopy twice

DRUGHyperpolarized Xenon129

Lung transplant recipient with hyperpolarized Xe129 in MRI as an inhalation contrast agent


Locations(1)

University of Virginia

Charlottesville, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07046910


Related Trials